BROSSARD, Quebec, March 27, 2019 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its proprietary FLAIRE platform based on Artificial Intelligence (AI), announces an update to provide more details with regards to the news release issued earlier today for the signing of a memorandum of understanding between one hospital in the US (the “Partner”) and DIAGNOS.
Memorandum of understanding
Main terms:
- Date of signature: March 22, 2019
- Partner and DIAGNOS (each a “Party”) agree to negotiate, in good faith, a specific agreement for establishing cooperative development and marketing effort for;
- any required development and inter-operability testing of CARDIO
- the granting of access to each Party’s facilities
- the co-marketing of CARDIO
DIAGNOS expects to sign a definitive agreement with Partner within 45 days from the date of this news release.
CARDIO
CARDIO is a software application, currently under development, to assist the health professionals in predicting the risk of a patient having a stroke or other conditions that may lead to a stroke. CARDIO was first announced in a press release dated September 19, 2017. DIAGNOS foresees full commercial deployment of CARDIO within six to twelve months from the date of this news release.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.